Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Ricolinostat

Generic Name: Ricolinostat

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₇N_₅O_₃

CAS Number: 1316214-52-4

Unique Ingredient Identifier: WKT909C62B

Overview

Ricolinostat is under investigation for the treatment of Breast Carcinoma and Metastatic Breast Cancer.

Background

Ricolinostat is under investigation for the treatment of Breast Carcinoma and Metastatic Breast Cancer.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study to Investigate the Safety and Efficacy of Ricolinostat

Phase 1

Completed

Posted: 2022/02/08

Sponsor:

Beijing 3E-Regenacy ...

ID:NCT05229042

Evaluate the Safety and Pharmacokinetics of Ricolinostat

Phase 1

Completed

Posted: 2022/01/18

Sponsor:

Beijing 3E-Regenacy ...

ID:NCT05193851

Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy

Phase 2

Completed

Posted: 2017/06/05

Sponsor:Regenacy Pharmaceuti...

ID:NCT03176472

Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma

Phase 1

Withdrawn

Posted: 2016/08/05

Sponsor:Mayo Clinic

ID:NCT02856568

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

Phase 1

Active, not recruiting

Posted: 2016/06/01

Sponsor:Dana-Farber Cancer I...

ID:NCT02787369

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy